Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
WALTHAM, Mass., Oct. 23, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Credit Suisse 26th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 6 and Tuesday, November 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat at 10:55 AM MT on Tuesday, November 7, and will also host meetings with investors.
- The Evercore ISI BioPharma Catalyst/Deep Dive Conference at the Boston Harbor Hotel in Boston on Wednesday, November 29. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat from 3:50 to 4:35 PM ET on Wednesday, November 29, and will also host meetings with investors.
Live webcasts of the presentations at the Credit Suisse and Evercore ISI conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or [email protected]
